Akzo Nobel Settles Antitrust Litigation Over Remeron Patents For $59.8M

Law360, New York (October 2, 2004, 12:00 AM EDT) -- Dutch conglomerate Akzo Nobel and its subsidiary Organon USA have agreed to settle litigation over its patents for antidepressant Remeron for $59.8 million, but the company still faces risks of class-action complaints.

The lawsuit alleged that Akzo’s assertion of the patent delayed the market introduction of mirtazapine, the generic name of the drug, and violated antitrust laws.

The settlement resolves direct claims brought by nine large chainstore and grocery store pharmacies, including Wal-Mart, and indirect claims brought by attorney general offices and third parties.

Akzo may...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.